- $81.64m
- -$65.78m
- 11
- 43
- 75
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.63 | ||
| Price to Tang. Book | 0.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.48% | ||
| Return on Equity | -64.42% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
Directors
- Mark Litton PRE (53)
- Glenna Mileson CFO (63)
- Rachel Lenington COO (48)
- Kevin Church VPR (36)
- Hans Moebius OTH (65)
- Grant Pickering DRC (53)
- Joseph Edelman IND (65)
- John Fluke IND (78)
- James Johnson IND (64)
- Barbara Kosacz IND (63)
- Kelly Romano IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 27th, 2015
- Public Since
- September 18th, 2020
- No. of Shareholders
- 42
- No. of Employees
- 65
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 38,326,652
- Address
- 18706 North Creek Parkway, BOTHELL, 98011
- Web
- https://www.athira.com/
- Phone
- +1 4256208501
- Contact
- Julie Rathbun
- Auditors
- Ernst & Young LLP
Upcoming Events for ATHA
Athira Pharma Inc Annual Shareholders Meeting
Athira Pharma Inc Annual Shareholders Meeting
Q2 2024 Athira Pharma Inc Earnings Release
Similar to ATHA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Athira Pharma share price?
As of Today at 19:03 UTC, shares in Athira Pharma are trading at $2.13. This share price information is delayed by 15 minutes.
How has the Athira Pharma share price performed this year?
Shares in Athira Pharma last closed at $2.13 and the price had moved by -18.08% over the past 365 days. In terms of relative price strength the Athira Pharma share price has underperformed the S&P500 Index by -31.83% over the past year.
What are the analyst and broker recommendations for Athira Pharma?
The overall consensus recommendation for Athira Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Athira Pharma dividend yield?
Athira Pharma does not currently pay a dividend.
Does Athira Pharma pay a dividend?
Athira Pharma does not currently pay a dividend.
When does Athira Pharma next pay dividends?
Athira Pharma does not currently pay a dividend.
How do I buy Athira Pharma shares?
To buy shares in Athira Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Athira Pharma?
As of the previous close price of $2.13, shares in Athira Pharma had a market capitalisation of $81.64m.
Where are Athira Pharma shares listed?
Here are the trading details for Athira Pharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ATHA
What kind of share is Athira Pharma?
Based on an overall assessment of its quality, value and momentum Athira Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Athira Pharma share price forecast for 2024?
The analyst consensus target price for shares in Athira Pharma is $7.42. That is 248.36% above the last closing price of $2.13.
Analysts covering Athira Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$3.24 for the next financial year.
What is the trend in the Athira Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Athira Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +12.32%.
As of the last closing price of $2.13, shares in Athira Pharma were trading -14.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Athira Pharma PE Ratio?
The Athira Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Athira Pharma?
Athira Pharma's management team is headed by:
- Mark Litton - PRE
- Glenna Mileson - CFO
- Rachel Lenington - COO
- Kevin Church - VPR
- Hans Moebius - OTH
- Grant Pickering - DRC
- Joseph Edelman - IND
- John Fluke - IND
- James Johnson - IND
- Barbara Kosacz - IND
- Kelly Romano - IND